The 2026 definition of ruxolitinib refractoriness in severe acute GVHD

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Malard F.
  • Chen Y.B.
  • Al Malki M.M.
  • Perales M.-A.
  • Peric Z.
  • Ruggeri A.
  • Brissot E.
  • Duarte R.
  • Morsink L.
  • Spyridonnidis A.
  • Battipaglia G.
  • Nakamura R.
  • Kharfan-Dabaja M.
  • Penak O.
  • Zeiser R.
  • Mohty M.

Grupos

Abstract

[No abstract available]

Datos de la publicación

ISSN/ISSNe:
0268-3369, 1476-5365

BONE MARROW TRANSPLANTATION  SPRINGERNATURE

Tipo:
Letter
Páginas:
972-974
PubMed:
42191985
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,998 SCImago ℠
Cuartil:
Q2 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • bilirubin; narcotic analgesic agent; ruxolitinib; transthyretin; ruxolitinib; abdominal pain; acute graft versus host disease; body weight loss; bullous skin disease; desquamation; drug toxicity and intoxication; drug withdrawal; dysbiosis; ECOG Performance Status; endothelium injury; erythrocyte concentrate; feces analysis; gastrointestinal acute graft versus host disease; gastrointestinal acute graft versus host disease; graft versus host reaction; hematochezia; human; hypoalbuminemia; Letter; malnutrition; nutritional status; sepsis; therapy resistance; toxicity; acute graft versus host disease; diagnosis; letter; therapy

Compartir